Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN6MT7
|
|||
| Drug Name |
OT-82
|
|||
| Synonyms |
1800487-55-1; N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-(pyridin-4-yl)benzamide; OT82; SCHEMBL16869651; NSC826040; NSC-826040; HY-136241; CS-0120951
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 1 | [1] | |
| Company |
OncoTartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H21FN4O
|
|||
| Canonical SMILES |
C1=CC(=CC=C1C#CC2=C(C=CC(=C2)C(=O)NCCCC3=CNN=C3)C4=CC=NC=C4)F
|
|||
| InChI |
1S/C26H21FN4O/c27-24-8-4-19(5-9-24)3-6-22-16-23(7-10-25(22)21-11-14-28-15-12-21)26(32)29-13-1-2-20-17-30-31-18-20/h4-5,7-12,14-18H,1-2,13H2,(H,29,32)(H,30,31)
|
|||
| InChIKey |
CEPAXRIKSUXHHB-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nicotinamide phosphoribosyltransferase (NAMPT) | Target Info | Inhibitor | [2] |
| BioCyc | NAD salvage | |||
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| IL1 Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| Pathwhiz Pathway | Nicotinate and Nicotinamide Metabolism | |||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| WikiPathways | Adipogenesis | |||
| Metabolism of water-soluble vitamins and cofactors | ||||
| Circadian Clock | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03921879) Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020 Jul;34(7):1828-1839. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.